Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer

Published:2021-08-12 Issue:18 Volume:10 Page:6304-6309
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Pobel Cedric¹^ORCID,Auclin Edouard¹,Teyssonneau Diego²,Laguerre Brigitte³,Cancel Mathilde⁴,Boughalem Elouen⁵,Noel Johanna¹,Brachet Pierre Emmanuel⁶,Maillet Denis⁷,Barthelemy Philippe⁸,Helissey Carole⁹^ORCID,Thibault Constance¹,Oudard Stéphane¹

Affiliation:

1. Oncology Department Hôpital Européen Georges PompidouAP‐HPUniversity of Paris Paris France

2. Oncology Department Bergonié Institut Bordeaux France

3. Oncology Department Eugène Marquis Center Rennes France

4. Oncology Department University hospital of Tours France

5. Oncology Department Institut de Cancérologie de l’Ouest Angers France

6. Oncology Department Centre François Baclesse Caen France

7. Oncology Department University hospital of Lyon France

8. Medical Oncology University Hospital Strasbourg / Institut de Cancérologie Strasbourg Europe Strasbourg France

9. Clinical Research Unit Military Hospital Begin Saint Mandé France

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4172

Reference15 articles.

1. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

2. Olaparib for Metastatic Castration-Resistant Prostate Cancer

3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

4. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA

5. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study);European Journal of Nuclear Medicine and Molecular Imaging;2024-07-15

2. Safety and Efficacy of Extended Therapy with [¹⁷⁷Lu]Lu-PSMA: A German Multicenter Study;Journal of Nuclear Medicine;2024-05-02

3. Fine-tuning the activation behaviors of ternary modular cabazitaxel prodrugs for efficient and on-target oral anti-cancer therapy;Asian Journal of Pharmaceutical Sciences;2024-04

4. Phytochemicals as Chemo-Preventive Agents and Signaling Molecule Modulators: Current Role in Cancer Therapeutics and Inflammation;International Journal of Molecular Sciences;2022-12-12

5. Cabazitaxel;Reactions Weekly;2021-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3